Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector Cells

Figure 4

Enavatuzumab treatment results in increased infiltration of CD45⁺ cells into tumors sensitive to antibody treatment. Established xenograft tumors were treated with enavatuzumab or a control antibody (a) or Fc mutants (b) on day 0 and day 2 or 3, and the tumors were harvested on day 4 for immunohistochemical staining for mouse CD45.

(a)

(b)